Drug news
NICE recommends Incivo (J&J Janssen Cilag) for genotype 1 chronic Hepatitis C patients
NICE has issued final draft guidance recommending Incivo (telaprevir), from J&J Janssen Cilag, in combination with Peg alfa and ribavirin, as an option for the treatment of in adults with compensated Liver Disease. It recommends the drug as an option for the treatment of such patients who are previously untreated or in whom previous treatment with Peg alfa and ribavirin has failed.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.